Anthropic Discusses Frontier AI Model Mythos With Trump Administration Despite Pentagon Ban 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
Amazon in Advanced Talks to Acquire Globalstar in Starlink Rivalry Move 
Baker Hughes Sells Waygate Technologies to Hexagon for $1.45 Billion 
Anthropic Nears $800 Billion Valuation as Investor Confidence Surges 
Jefferies Upgrades Starbucks to Hold as China JV Deal Closes and U.S. Business Shows Signs of Recovery 
Chinese Cars in Europe: Consumer Trust Is Shifting Fast 
SK Hynix Shares Hit Record High Amid AI Memory Demand Surge 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
Nissan Plans Major Lineup Cuts and AI Expansion in Bid for Global Sales Recovery 
TSMC Posts Record Q1 2026 Profits Driven by Surging AI Chip Demand 
CANTON, Mass., April 08, 2016 -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that Michael Heffernan, the Company’s CEO, will present at the 15th Annual Needham Healthcare Conference in New York City. The presentation will take place at 1:40 p.m. ET on Wednesday, April 13, 2016 at the Westin Grand Central Hotel.
About Collegium Pharmaceutical, Inc.
Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETERx® technology platform for the treatment of chronic pain and other diseases. The DETERx oral drug delivery technology is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.
About Xtampza™ ER
Collegium's lead product candidate, Xtampza ER, is an abuse-deterrent, extended-release, oral formulation of oxycodone, in development for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Collegium developed Xtampza using its proprietary DETERx technology platform to address common methods of abuse, including chewing, crushing and/or dissolving, and then taking it orally or snorting or injecting.
Contact: Douglas Carlson Vice President, Corporate Development [email protected]
